A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
This study is currently enrolling.
This study is for an investigational study drug called poziotinib for the treatment for EGFR or HER2 Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer. Poziotinib is a new type of treatment and is considered invest ...